Skip to main content
. 2022 Jan 7;17(1):e0262455. doi: 10.1371/journal.pone.0262455

Fig 2. Prognostic impact of TLS in GC.

Fig 2

(A) Kaplan-Meier plots using the log-rank test for OS and PFS according to the percent area of TLS. Patients with TLS high had a better prognosis than those with TLS low (a: OS; p = 0.045). Patients with TLS high tended to have a better prognosis (b: PFS; p = 0.1752). (B) Kaplan-Meier plots using the log-rank test for OS according to the combination of TLS and CD103+ T cells. (a) Patients with TLS high and CD103 high tended to have a better prognosis than other groups. (b-d) There was not a statistically significant difference in PFS on 1st- and 2nd-line chemotherapy and nivolumab therapy. When nivolumab therapy was used as the starting time of PFS, individuals with high TLS and high CD103 tended to have longer PFS.